Medpace Holdings, Inc. vs UL Solutions Inc., two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where MEDP and ULS diverge most: on debt / equity, MEDP reads 0.00 and ULS reads 0.27; on return on invested capital, MEDP reads 107.6% and ULS reads 24.5%. The rest of the comparable metrics sit closer together. What MEDP's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | MEDP | ULS |
|---|---|---|
| Price | $577.05 | $91.78 |
| Market cap | $16.1B | $18.7B |
| Sector | Biotechnology | Biotechnology |
| Stage | Growth | Mature |
| Implied growth (priced in) | +32.9% | — |
| P/E | 33.9 | 53.4 |
| P/B | 37.12 | 14.01 |
| P/S | 5.79 | 6.03 |
| EV/EBITDA | 25.6 | 31.5 |
| Revenue growth | +24.9% | +6.9% |
| Operating margin | 20.8% | 18.2% |
| Net margin | 17.7% | 11.3% |
| Return on equity | 113.3% | 26.2% |
| Return on assets | 23.9% | 11.8% |
| Return on invested capital | 107.6% | 24.5% |
| FCF yield | 4.4% | 2.4% |
| Dividend yield | — | 0.6% |
| Debt / equity | 0.00 | 0.27 |
| Current ratio | 0.73 | 1.16 |
| Altman Z (solvency) | 6.97 | 7.52 |
| Piotroski F (quality) | 8 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.